Presence of Two Different Genetic Traits in Malignant Hyperthermia Families
Open Access
- 1 November 2002
- journal article
- research article
- Published by Wolters Kluwer Health in Anesthesiology
- Vol. 97 (5) , 1067-1074
- https://doi.org/10.1097/00000542-200211000-00007
Abstract
Background: Malignant hyperthermia susceptibility (MHS), an uncommon syndrome often inherited as an autosomal dominant trait, is characterized by a genetic and clinical heterogeneity. In this article, the authors described six pedigrees in which both parents of MHS patients were diagnosed with MHS by an diagnostic test. Haplotype and mutation analysis revealed that more than one MHS genetic trait was present in these families. Methods: A panel of 104 MHS families were investigated with a caffeine halothane contracture test on muscle biopsy specimens. When possible, blood creatine kinase concentrations of MHS patients were measured. Haplotyping studies were conducted with chromosome 19q13.2 polymorphic markers and mutations were searched for in patients' DNA. Results: In six families, the diagnostic test and genetic studies demonstrated that both, apparently unrelated, parents of MHS patients were MHS. In three families, homozygous or compound heterozygous individuals for RYR1 mutations were characterized at a molecular level. In one family, a compound heterozygous patient harboring a RYR1 mutation and a CACNA1S mutation was identified. While patients with two mutated alleles did not show differences in their muscle response to halothane or caffeine, their creatinine kinase concentrations were significantly elevated compared with the heterozygous patients. Conclusions: Based on genetic and diagnostic test data, more than one MHS allele associated with the MHS phenotype was evidenced in four families. These data should be considered in view of the use of genetics for the diagnosis of MHS and when reaching conclusions of genetic heterogeneity in MHS families. Taking into account the usual dominant mode of transmission of MHS and the size of the investigated population, the authors propose an evaluation of the incidence of the MHS in the general population based on genetic data.Keywords
This publication has 29 references indexed in Scilit:
- A novel ryanodine receptor mutation and genotype-phenotype correlation in a large malignant hyperthermia New Zealand Maori pedigreeHuman Molecular Genetics, 2000
- Ryanodine receptor mutations in malignant hyperthermia and central core diseaseHuman Mutation, 2000
- Malignant hyperthermia in infancy and identification of novel RYR1 mutationBritish Journal of Anaesthesia, 2000
- Screening of the ryanodine receptor gene in 105 malignant hyperthermia families: novel mutations and concordance with the in vitro contracture testHuman Molecular Genetics, 1999
- Localization of the malignant hyperthermia susceptibility locus to human chromosome 19ql2–13.2Nature, 1990
- Ryanodine receptor gene is a candidate for predisposition to malignant hyperthermiaNature, 1990
- Standardization of the Caffeine Halothane Muscle Contracture TestAnesthesia & Analgesia, 1989
- A PROTOCOL FOR THE INVESTIGATION OF MALIGNANT HYPERPYREXIA (MH) SUSCEPTIBILITYBritish Journal of Anaesthesia, 1984
- Malignant hyperthermia: A statistical reviewCanadian Journal of Anesthesia/Journal canadien d'anesthésie, 1970
- ANÆSTHETIC DEATHS IN A FAMILYThe Lancet, 1960